A double-blind double-dummy study of citalopram comparing infusion versus oral administration

Journal of Affective Disorders

Volumn 49, Issue 3, 1998, Pages 203-210

  Baumann, P ^a   Nil, R ^b   Bertschy, G ^a   Jecker, A ^c   Brandli H ^d   Morand, J ^d   Kasas, A ^e   Vuagniaux, O ^f   Ramseier, F ^g  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b H LUNDBECK A S   (Denmark)

^c Psychiatrische Klinik Meisenberg   (Switzerland)

^d Hôpital Psychiatrique Cantonal   (Switzerland)

^e Clinique Psychiatrique Cantonale   (Switzerland)

^f Centre Psycho social   (Switzerland)

^g Psychiatrische Dienste Aargau AG   (Switzerland)

Author keywords

Citalopram; Depressive patients; Infusion; Pharmacokinetics; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; AMNESIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 0031970489     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(98)00024-X     Document Type: Article

References (20)

1. Baumann P., Nil R., Souche A.et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depression patients: a clinical pharmacokinetic, and pharmacogenetic investigation. Journal of Clinical Psychopharmacology. 16(4):1996;307-314.
2. Baumann P., Larsen F. The pharmacokinetics of citalopram. Rev. Contemp. Pharmacother. 6:1995;287-295.
3. Baumann P., Meyer J.W., Amey M.et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther. Drug. Mont. 44:1992;1-8.
4. Bech P., Cialdella P. Citalopram in depression-meta-analysis of intended and unintended effects. Clinical Neuroscience Publications. 5(Suppl. 5):1992;45-54.
5. Bouchard J.M., Bellazanz D., Charbonnier J.F.et al. Citalopram and viloxazine n the treatment of depression by means of slow drop infusion: A double-blind comparative trial. J. Affect. Disord. 46:1997;51-58.
6. Dencker, S.J., Høpfner Petersen, H.E., 1988. Side effect profile of citalopram and reference antidepressants in depression. In: Montgomery S. (Ed.), Citalopram - The New Antidepressant from Lundbeck Research. Excerpta Medica, Amsterdam, The Netherlands, pp 31-42.
7. Enemark B. The importance of ECG monitoring in antidepressant treatment. Nord. J. Psychiatry. 47(30):1993;57-65.
8. Guy, W., (Ed.) 1976. ECDEU Assessment Manual for Psychopharmacology, National Institute for Mental Health, Rockville, MD, USA.
9. Hamilton, M., 1967. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6 (1976) 278-296.
10. Jungkunz, G., Kuss, H.J., Dieterle, D., 1984. Vergleich der Infusionbehandlung mit der peroralen Applikation von Clomiprarnin bei endogen depressiven Patienten. In: Kielholz, P., Adams, C. (Hrsg.): Tropfinfusionen in der Depressionsbehandlung, Thieme, Stuttgart.
11. Kissling W., Møller H.J., Lauter H.et al. Double-blind comparision of intravenous versus oral maprotiline. Antidepressant activity, plasma levels, side effects. Pharmacopsychiatry. 15:1985;96-97.
12. Laux, G., König, W., Baumann, P., 1997. Infusionstherapie bei Depressionen: Ein Leitfaden für Klinik und Praxis. 4. Aufl., Hippokrates Verlag, Stuttgart.
13. Laux G., König W., Lesch K.P.et al. Intravenöse versus orale Behandlung endogen depressiver Patienten mit Doxepin - eine Doppelblindstudie mit Plasmaspiegelbestimmungen. Wiener Medizinische Wochenschrift. 139:1989;525-529.
14. Lingjaerde, D., Ahlfors, U.G., Bech, P., et al., 1987. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and cross sectional study of side effects in neuroleptic treated patients. Acta. Psychiatr. Scand. 76 (Suppl. 334).
15. Milne R.J., Goa K.L. Citalopram, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drug. 41:1991;450-477.
16. Montgomery S.A., Pedersen V., Tanghøj P.et al. The optimal dosing regimen for citalopram - A meta-analysis of nine placebo-controlled studies. Int. Clin. Psychopharmacol. 9(Suppl. 1):1994;35-40.
17. Pollock B.G., Perel J.M., Kupfer D.et al. Early response patterns associated with successful clomipramine treatment. J. Clinical Psychopharmacology. 13(6):1993;442-447.
18. Pollock B.G., Perel J.M., Nathan R.S.et al. Acute antidepressant effect following pulse loading with intravenous and oral clomipramine. Arch. Gen. Psychiatry. 46(1):1989;29-35.
19. Reymond P., Amey M., Souche A.et al. Determination of plasma levels of citalopram and its demethylated and deaminated metabolites by gas chromatography and gas chromatography-mass spectrometry. J. Chromatogr. Biomed. Appl. 616:1993;221-228.
20. Rochat B., Amey M., Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Therap. Drug Monitoring. 17:1995;273-279.